Education
About Us
Working with TipRanks
Follow Us
Shilpa Medicare Limited (IN:SHILPAMED)
:SHILPAMED
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹501.60
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹61.54B
Enterprise Value₹67.31B
Total Cash (Recent Filing)₹535.50M
Total Debt (Recent Filing)₹5.93B
Price to Earnings (P/E)35.2
Beta0.97
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)2.28
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.70
Price to Sales (P/S)4.98
P/FCF Ratio-57.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.9
Revenue Forecast (FY)₹14.68B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 68.12% gross margin reflects durable pricing power from complex APIs and specialty formulations. High product-level margins provide a structural buffer against input cost swings and support long-term profitability as oncology and complex therapies command premium pricing in regulated markets.
Specialty/Oncology Focus & CDMO CapabilitiesConcentration on oncology and complex therapies, plus CDMO/CRAMS capabilities, creates structural competitive advantage: high technical barriers, regulatory know‑how and long-term supply agreements increase switching costs and foster stable, repeatable revenue from regulated markets.
Improved Balance Sheet And Low LeverageSignificantly reduced leverage and a strong equity ratio provide durable financial flexibility. Lower debt reduces refinancing risk, supports continued R&D/CapEx investment in complex manufacturing, and increases resilience to industry cycles or regulatory delays over the medium term.
Bears Say
Falling Operating ProfitabilityA marked drop in EBIT margin signals structural pressure on operating efficiency—higher opex or scaling expenses are eroding operating leverage. If sustained, this weakens the company's ability to convert strong gross profits into durable operating income and limits reinvestment capacity.
Negative Free Cash Flow From Heavy CapExSubstantial capex driving negative free cash flow creates a persistent liquidity strain despite operating cash generation. Continued negative FCF may require external financing or slower shareholder returns and raises execution risk if investments fail to generate expected returns within a medium-term horizon.
Modest Returns On EquityROE remains low despite improvement, indicating limited efficiency in translating equity into profits. Over months, modest ROE and a net margin of ~6% constrain shareholder returns and may signal that capital allocation or pricing strategies need strengthening to deliver competitive long-term returns.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹501.60 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹61.54B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is May 21, 2026 which is in 61 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Feb 06, 2026. The company reported ₹2.28 earnings per share for the quarter, missing the consensus estimate of ₹2.8 by -₹0.52.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.16%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹2.28 in its last earnings report, missing expectations of ₹2.8. Following the earnings report the stock price went down -0.663%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―